MedTrace Logo

iStent Inject in OAG Subjects on 2 Pre-op Topical Ocular Hypotensive Medications

NCT03478293 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2022-09-09

No results posted yet for this study

Summary

The purpose of this study is to evaluate the intraocular pressure (IOP) lowering effect of iStent inject in eyes of subjects with primary open-angle glaucoma previously on two anti-glaucoma medications.

Conditions

  • Primary Open Angle Glaucoma (POAG)

Interventions

DEVICE

iStent inject surgery

Micro-invasive glaucoma surgery (MIGS) to implant iStent inject

Sponsors & Collaborators

  • Glaukos Corporation

    lead INDUSTRY

Principal Investigators

  • Kerry Stephens, OD · Glaukos Corporation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-02-27
Primary Completion
2020-12-30
Completion
2020-12-30
FDA Device
Yes

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03478293 on ClinicalTrials.gov